RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:34:52·⟳ 抓取 22:45:20 +2h10m·⚡ 决策 10-08 22:46:23 +1m03s·19.1 天前
Viatris以16.5亿美元、每股36.50美元现金收购Pacira BioSciences
被收购方PCRX股价已基本完全收敛至要约价，套利空间不足0.6%却需承担审批与交易破裂风险；收购方VTRS股价当日不涨反跌，无短线正edge。
📄 原文RTTNews Biotech↗ 原文
Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Pacira BioSciences（PCRX.US）
现价36.295美元已贴近36.50美元要约价，剩余空间仅约0.57%，却需持有至年底并承担监管审批与交易破裂风险，无套利edge。
不做 Viatris（VTRS.US）
收购属温和中性且需动用现金与短期借款，盘中股价下跌1.66%，市场反应偏负，缺乏短线做多催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是一笔已签约、溢价约44%的现金收购，消息在盘前已充分定价：PCRX盘中36.295美元贴近36.50美元要约价，套利收益微薄；VTRS反而下跌1.66%。两边均无正期望，回避。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 high · price-in 风险 high ↗
关键理由
- PCRX现价较要约价仅余约0.57%空间，而交割需等到年底，承担监管与破裂风险不补偿。
- VTRS收购整合与增厚属温和中性，市场用下跌表达态度，缺乏短线做多催化。
主要风险
- 若交易出现反垄断障碍或融资问题，PCRX可能从接近36.50美元大幅回落至25美元附近。
- 若交割超预期顺利，PCRX仅能赚取不足0.6%的收敛收益，扣成本后接近为零。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
PCRX现价已含全部溢价，剩余收益不足以补偿审批/融资/破裂风险；VTRS盘中下跌，市场不认可短线利好。
检索:PCRX VTRS deal antitrust regulatory risk financing 原文 ↗
先例如何影响了这次决策
对本次决策的影响:因PCRX剩余空间不足0.6%、VTRS当日下跌，无需先例即可判定无正期望，直接回避。
涨幅量级:无可用对齐先例；但本案不依赖先例——现金固定要约收购的剩余收益可直接由现价与要约价差计算。
形态:不适用，价格已收敛至要约价，属典型并购套利结构而非事件驱动追涨。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 18 ms
{"result": "search_processed_events:agent query=`viatris acquire pacira biosciences $36.50 per share cash | vtrs pcrx merger $1.65 billion exparel zilretta`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 134 ms
{ - stock_quote 成功 stock_tools HTTP · 117 ms
{
原文全文
展开原文 · 7,495 字
Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Quick Facts
Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal
By
RTTNews Staff Writer
✉
Published:
10/8/2026 8:34 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Thursday, Viatris Inc. (
VTRS
) announced an agreement to acquire all of the outstanding shares of common stock of Pacira BioSciences, Inc. (
PCRX
), a biopharmaceutical company focusing on innovative non-opioid pain therapies, for $36.50 per share in a cash deal.
The $1.65 billion deal adds Pacira's two established, high-margin, patent-protected, in-market U.S. products - EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain, to the company's portfolio, which is expected to position Viatris as a leader in non-opioid pain management therapies.
In addition to these products, Pacira brings Viatris U.S. innovative commercial, market access, medical affairs and global R&D capabilities that are highly complementary to the company's existing infrastructure and portfolio.
The company plans to fund the transaction primarily from excess cash, with the remainder from short-term borrowings.
Set to close by 2026 end, the deal is expected to be immediately accretive to the company's financial guidance metrics.
Post-acquisition, Pacira will become a wholly owned subsidiary of Viatris and Pacira's common stock will no longer be listed for trading on the Nasdaq Global Select Market.
In pre-market hours, VTRS was trading at $17.50, up 0.06 percent, and PCRX was trading at $36.33, up 44.17 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
Invest in the Best Biotech Stocks by Subscribing to
RTT Biotech Investor
.
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Previous Story
Next Story
Latest Updates on Middle East War
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
U.S. Stocks Under Pressure As Crude Oil Prices, Treasury Yields Surge
September 28, 2026 11:06 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal
Viatris Posts Wider Loss In Q2; Raises 2026 Guidance
Viatris Q2 26 Earnings Conference Call At 8:30 AM ET
Viatris Secures FDA Approval For Gwyn Lo Contraceptive Patch
Latest Updates on COVID-19
View More
Most Read
Most Emailed
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Quick Facts
Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal
By
RTTNews Staff Writer
✉
Published:
10/8/2026 8:34 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Thursday, Viatris Inc. (
VTRS
) announced an agreement to acquire all of the outstanding shares of common stock of Pacira BioSciences, Inc. (
PCRX
), a biopharmaceutical company focusing on innovative non-opioid pain therapies, for $36.50 per share in a cash deal.
The $1.65 billion deal adds Pacira's two established, high-margin, patent-protected, in-market U.S. products - EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain, to the company's portfolio, which is expected to position Viatris as a leader in non-opioid pain management therapies.
In addition to these products, Pacira brings Viatris U.S. innovative commercial, market access, medical affairs and global R&D capabilities that are highly complementary to the company's existing infrastructure and portfolio.
The company plans to fund the transaction primarily from excess cash, with the remainder from short-term borrowings.
Set to close by 2026 end, the deal is expected to be immediately accretive to the company's financial guidance metrics.
Post-acquisition, Pacira will become a wholly owned subsidiary of Viatris and Pacira's common stock will no longer be listed for trading on the Nasdaq Global Select Market.
In pre-market hours, VTRS was trading at $17.50, up 0.06 percent, and PCRX was trading at $36.33, up 44.17 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
Invest in the Best Biotech Stocks by Subscribing to
RTT Biotech Investor
.
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Previous Story
Next Story
Latest Updates on Middle East War
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
U.S. Stocks Under Pressure As Crude Oil Prices, Treasury Yields Surge
September 28, 2026 11:06 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Viatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal
Viatris Posts Wider Loss In Q2; Raises 2026 Guidance
Viatris Q2 26 Earnings Conference Call At 8:30 AM ET
Viatris Secures FDA Approval For Gwyn Lo Contraceptive Patch
Latest Updates on COVID-19
View More
Most Read
Most Emailed
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
e296490ef9· 2026-10-08 22:46 · doubao / doubao-seed-evolving-latest-version · 策略包0c89ec5cee9e当前